UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2023 |
PROKIDNEY CORP.
(Exact name of Registrant as Specified in Its Charter)
Cayman Islands | 001-40560 | 98-1586514 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
2000 Frontis Plaza Blvd. Suite 250 |
| |||
Winston-Salem, North Carolina |
| 27103 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: 336 999-7029 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Class A ordinary shares, $0.0001 par value per share |
| PROK |
| The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 29, 2023, ProKidney Corp. (the “Company”) held its 2023 Annual General Meeting of Shareholders (the “Annual General Meeting”). The matters voted on at the Annual General Meeting and the votes cast with respect to each such matter are set forth below:
Director Nominee | | For |
| | Against |
| | Abstain |
|
| Broker Non Votes |
| ||||
William F. Doyle | |
| 204,688,357 |
| |
| 86,755 |
| |
| 59,329 |
| |
| 6,436,976 |
|
Alan M. Lotvin, M.D. | |
| 204,717,013 |
| |
| 86,192 |
| |
| 31,236 |
|
|
| 6,436,976 |
|
Brian J. G. Pereira, M.D. | |
| 204,658,435 |
| |
| 84,994 |
| |
| 91,012 |
| |
| 6,436,976 |
|
For |
| | Against |
| | Abstain |
|
| Broker Non Votes |
| ||||
| 211,255,952 |
| |
| 15,231 |
| |
| 234 |
| |
| – |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| PROKIDNEY CORP. |
|
|
|
|
Date: | June 30, 2023 | By: | /s/ James Coulston |
|
|
| James Coulston |